Cancer Guidelines Database

This is a clinical practice guideline for females who are survivors of childhood, adolescent, and young adult (CAYA) cancers. The guideline provides recommendations for the surveillance and counseling of these patients during pregnancy and delivery, in order to minimize obstetrical risks and reduce adverse pregnancy outcomes. Specific outcomes addressed include miscarriages, terminations, still births, hypertensive disorders of pregnancy, pre-eclampsia, gestational diabetes, premature birth, low birth weight, and more.

This is a clinical practice guideline for children and young adults with aggressive mature B-cell lymphomas, including Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). The guideline discusses the pathology and diagnosis, staging, initial treatment, disease reassessment, surveillance, therapy for relapsed/refractory disease, and supportive care for these patients. Specific recommendations are provided based on disease type and stage.

This is a clinical practice guideline for patients with prostate cancer. The guideline examines the diagnosis, classification and staging, treatment, and follow-up of these patients. Quality of life outcomes are also discussed. This is a web-based guideline and may be updated as new evidence arises - this review pertains to the guideline as of February 12, 2021.

This is a clinical practice guideline for adults with cancer who are receiving chemotherapy and/or monoclonal antibodies. The guideline examines acute infusion-related allergic and allergic-like reactions in these patients. Acute infusion-related adverse events terminology, risk factors, incidence and characteristics are discussed, including unique characteristics for each main drug class. The management and follow-up of acute infusion-related adverse events are also considered.

This is a clinical practice guideline for patients with gastric cancer. The guideline examines the pathology, initial workup, staging, treatment, follow-up, and supportive care of these patients. Treatment options discussed include lymph node dissection, laparoscopic resection, endoscopy, radiation therapy, combined modality therapy, chemotherapy (preoperative, perioperative, and postoperative), and targeted therapies.

This is a clinical practice guideline for children with cancer. The guideline examines the prevention and management of pain and distress related to needle procedures in these patients. Interventions discussed include topical anesthetics, sedation for major procedures, sedation for lumbar punctures, sedation for minor procedures, oral analgesics for minor procedures, hypnosis, as well as active and passive distraction. Education and preparation, empowerment, the presence of parents, and ongoing pain assessments are also considered.

This is a clinical practice guideline for adults and children experiencing cancer-related fatigue (CRF). The guideline discusses screening for CRF, as well as evaluation approaches using focused history, assessment of treatable contributing factors, and patient clinical status. General strategies for managing CRF are discussed, and the guideline examines pharmacological and non-pharmacological treatments for patients based on their placement within the care continuum (i.e. active treatment, post-treatment, and end-of-life).

This is a clinical practice guideline for adults with advanced colorectal cancer. The guideline aims to improve the quality of life for these patients by integrating an early palliative care approach into advanced cancer care. The indications for the need to apply an early, integrated palliative approach, and the essential components of such care, are specifically addressed.

This is a clinical practice guideline for adult cancer patients who are at any phase of the cancer care continuum, regardless of cancer type. The guideline provides recommendations for the screening and treatment of tobacco use in these patients. Outcomes of interest include improved treatment effectiveness, decreased risk of cancer recurrence, decreased treatment-related toxicity, decreased risk of second primary cancer, and decreased mortality.

This is a clinical practice guideline for children and adults who have a hematological malignancy or solid tumour. The guideline provides recommendations for influenza immunization in these patients as they are undergoing cancer treatment. Specific topics addressed include the timing of immunization, contraindications for immunization, the immunization of family members and hospital/clinic staff, and the effects of age and type of therapy (e.g., systemic therapy, hematopoietic stem cell transplantation) on the decision to immunize.

This is a clinical practice guideline for patients with AIDS-related Kaposi sarcoma. The guideline examines diagnosis, staging, treatment, and follow-up, while also providing recommendations on HIV screening and HIV therapy during cancer treatment. Antiretroviral therapy (ART), topical therapies, intralesional chemotherapy, local incisions, radiation therapy, and systemic therapy are all discussed as treatment options.

This is a clinical practice guideline for the assessment and management of breathlessness in patients with cancer. The guideline examines both non-pharmacological and pharmacological options for these patients. Non-pharmacological interventions including fan or airflow, breathing re-training, education and self-management, pulmonary rehabilitation and complementary therapies are discussed, as are pharmacological interventions such as opioids, benzodiazepines, corticosteroids, supplemental oxygen, antidepressants and cannabinoids. Treatment of the underlying causes of breathlessness and the impact of breathlessness on caregivers are also considered.

This is a clinical practice guideline for patients with acute lymphoblastic leukemia or acute myeloid leukemia. The guideline examines immunotherapy options for the treatment of these patients. Topics of interest include allogenic cell transplantation in combination with immunotherapy, the management of immune-related adverse events, emerging immunotherapies, and patient support.

This is a clinical practice guideline for adolescents and young adults with cancer. The guideline discusses risk factors, screening, diagnosis, management, follow-up, supportive care, and palliative care for patients between 15 and 39 years of age. Unique issues discussed include adherence to treatment, the impact of cancer and its treatment on fertility, management of cancer during pregnancy, relationship management, and socioeconomic issues.

This is a clinical practice guideline for patients living with HIV (PLWH) who are diagnosed with cancer. The guideline focuses primarily on PLWH who develop non-small cell lung cancer (NSCLC), anal cancer, Hodgkin lymphoma, or cervical cancer. General advice is also provided regarding HIV management during cancer therapy, in addition to topics such as drug-drug interactions (DDI) between antiretroviral treatments and cancer therapies, initial workup, radiation therapy, surgical management, and supportive care.

This is a clinical practice guideline for adult patients undergoing immune checkpoint inhibitor treatment. The guideline examines the investigation and management of immune checkpoint inhibitor-induced enterocolitis in these patients. Diagnostic tests, histopathology, cross-sectional imaging, fecal calprotectin and lactoferrin, excluding gastrointestinal infection, and other investigations are considered, as well as management with corticosteroids, infliximab, vedolizumab, and other therapeutic options. Corticosteroid withdrawal in patients requiring biologic therapy, surgery for immune checkpoint inhibitor-induced colitis, management of microscopic inflammation, nutritional support, management of symptomatic relapse, and considerations for patients with multiple organ involvement are also discussed.

This is a clinical practice guideline for patients with head and neck cancers. The guideline examines workup and staging, treatment, and follow-up for various head and neck cancers including cancer of the lip, oral cavity, oropharynx, hypopharynx, nasopharynx, and larynx, as well as paranasal tumours, very advanced head and neck cancers, occult primary cancer, salivary gland tumours, and mucosal melanoma of the head and neck. Nutrition, supportive care, comorbidities, quality of life, and dental evaluation and management are also discussed.

This is a clinical practice guideline for patients with any type of cancer who are experiencing or are at high risk for experiencing nausea and/or vomiting due to treatment. The guideline examines treatment options for nausea and/or vomiting induced by radiation therapy (RT), chemotherapy, targeted therapy, and immunotherapy. In addition to antiemetic treatment options, the guideline discusses the emetogenic potentials of different anticancer therapies.

This is a clinical practice guideline for patients aged 15-39 years who have been diagnosed with cancer. The guideline discusses screening and assessment strategies, access and participation in clinical trials, as well as approaches to treatment in this patient population. Additional topics addressed include the facilitation of psychosocial care, survivorship care planning, and the optimization of palliative care.

This is a clinical practice guideline for the identification and treatment of psychosocial problems in patients with cancer. The guideline examines screening tools for distress and meeting psychosocial needs, the initial evaluation and treatment by oncology teams, psychological/psychiatric treatment by mental health professionals, social work and counseling services, and spiritual and chaplaincy care. The Distress Thermometer (DT) is discussed as a useful clinical tool for self-assessing patient distress. Both the DT and the guideline itself use the term "distress" due to its lack of associated stigmatization when compared to terms such as psychosocial, psychiatric, or emotional.

This is a clinical practice guideline for patients with hematological or solid tumour malignancies who are receiving chemotherapy and are at risk for hepatitis B virus (HBV) reactivation. The guideline discusses who to test for HBV infection, when to start antiviral agents, when to stop antiviral agents, and how to monitor patients during treatment.

Tailored to the unique needs and concerns of patients with all types of cancer, this clinical practice guideline provides standard-of-care recommendations, techniques, and strategies on smoking cessation. The guideline outlines different interventions, including pharmacotherapy options (e.g. nicotine replacement therapy, varenicline, bupropion, nortriptyline, clonidine), motivational strategies and behaviour techniques, and alternative treatment approaches such as electronic cigarettes and other electronic nicotine delivery systems.

This is a clinical practice guideline for the identification and treatment of psychosocial problems in patients with cancer. The guideline examines screening tools for distress and meeting psychosocial needs, the initial evaluation and treatment by oncology teams, psychological/psychiatric treatment by mental health professionals, social work and counseling services, and spiritual and chaplaincy care. The Distress Thermometer (DT) is discussed as a useful clinical tool for self-assessing patient distress. Both the DT and the guideline itself use the term "distress" due to its lack of associated stigmatization when compared to terms such as psychosocial, psychiatric, or emotional.

This is a clinical practice guideline for patients with gastric cancer. The guideline examines the pathology, initial workup, staging, treatment, follow-up, and supportive care of these patients. Treatment options discussed include lymph node dissection, laparoscopic resection, endoscopy, radiation therapy, combined modality therapy, chemotherapy (preoperative, perioperative, and postoperative), and targeted therapies.

This is a clinical practice guideline for patients living with HIV (PLWH) who are diagnosed with cancer. The guideline focuses primarily on PLWH who develop non-small cell lung cancer (NSCLC), anal cancer, Hodgkin lymphoma, or cervical cancer. General advice is also provided regarding HIV management during cancer therapy, in addition to topics such as drug-drug interactions (DDI) between antiretroviral treatments and cancer therapies, initial workup, radiation therapy, surgical management, and supportive care.

This is a clinical practice guideline for adolescent, young adult (AYA), and adult patients with acute lymphoblastic leukemia (ALL). The guideline reviews the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers, and provides recommendations on risk assessment and stratification for risk-adapted therapy, as well as treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL. The guideline also provides recommendations for supportive care.

This is a clinical practice guideline for adults with primary sclerosing cholangitis (PSC) or those presenting with similar cholangiopathies which may mimic PSC, such as IgG4-related sclerosing cholangitis. The guideline examines the diagnosis and management of these patients, including the role of liver biopsy, non-invasive assessment of liver fibrosis, overlap syndromes, the role of endoscopy, ERCP and endotherapy, specialist referral, liver transplantation, and the management of complications. Screening for cancer in PSC, pregnancy in women with PSC, patient perspectives and support groups, and service standards, are also discussed.

A clinical practice guideline on the diagnosis, workup, treatment and surveillance of B-cell lymphoma (BCL) in pediatric and adult patients. The guideline focuses on the most common B-cell lymphomas: follicular lymphoma (FL), marginal zone lymphomas (MZL), nodal MZL, splenic MZL, gastric MALT lymphoma, mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), AIDS-related B-cell lymphoma, post-transplant lymphoproliferative disorders, and Castleman's disease. Additional consideration is paid to the classification systems used in NHL, the role of PET scans in assessment and staging, principles of radiation therapy, and supportive care considerations.

This is a clinical practice guideline for adult patients with oropharyngeal cancer. The guideline discusses the diagnostic investigations and baseline assessments that should be used for patients with suspected or confirmed oropharyngeal cancer, as well as treatment options for early (stage I and II), locally advanced (stage III and IV), metastatic, and recurrent oropharyngeal cancer. Post-treatment rehabilitation and follow-up strategies are also examined.

This is a clinical practice guideline for patients with acute myeloid leukemia (AML), including those with acute promyelocytic leukemia (APL). The guideline examines the initial evaluation of AML, risk stratification based on cytogenetics and molecular markers, management options, as well as supportive care. Management strategies are separated based on whether patients are above or below sixty years of age.

This is a clinical practice guideline for adults with any type of cancer. The guideline focuses on the screening, assessment, and treatment of cancer-related pain. Specific topics discussed include universal pain screening, management of pain in both opioid-naïve and opioid-tolerant patients, management of opioid-induced adverse effects, procedure-related pain and anxiety, management strategies for specific cancer pain syndromes, adjuvant analgesics for neuropathic pain, psychosocial support, and education for both patients and caregivers.

This is a clinical practice guideline for patients with multiple myeloma. The guideline examines the primary therapy and surveillance/follow-up tests for both solitary plasmacytoma and smoldering (asymptomatic) myeloma, and the primary therapy and monitoring for active (symptomatic) myeloma. Stem cell transplants (SCT), including autologous SCT, tandem SCT, and allogeneic SCT, as well as follow-up after stem cell transplants, are also discussed. In addition, the guideline considers diagnostic tests, response criteria, maintenance therapy, treatment of progressive or relapsed myeloma, and supportive care treatment.

This is a clinical practice guideline for patients with head and neck cancers. The guideline examines workup and staging, treatment, and follow-up for various head and neck cancers including cancer of the lip, oral cavity, oropharynx, hypopharynx, nasopharynx, and larynx, as well as paranasal tumours, very advanced head and neck cancers, occult primary cancer, salivary gland tumours, and mucosal melanoma of the head and neck. Nutrition, supportive care, comorbidities, quality of life, and dental evaluation and management are also discussed.

This is a clinical practice guideline for patients with hairy cell leukemia. The guideline provides recommendations regarding diagnosis, initial treatment, response assessment and additional therapy, second-line therapy for relapsed/refractory or progressive disease, and supportive care. The impact of infections, such as hepatitis B (HBV) is also discussed.

This is a clinical practice guideline for women with cervical cancer. The guideline examines the initial diagnosis and workup, staging, primary and adjuvant treatment, surveillance, and therapy following relapse for these patients. Treatment for metastatic disease is also discussed, as are the topics of incidental cervical cancer and the occurrence of cervical cancer in pregnant women.

This is a clinical practice guideline for older patients with cancer. The guideline provides recommendations for comprehensive geriatric assessments, as well as treatment modalities such as surgery, radiation therapy (RT), chemotherapy, and targeted therapy. Disease-specific issues are also addressed for breast cancer, central nervous system cancers, gastrointestinal cancers, genitourinary cancers, gynecological cancers, head and neck cancers, lung cancers, melanoma, and hematologic malignancies.

This is a clinical practice guideline for patients with myeloproliferative neoplasms. The guideline specifically examines the diagnosis, risk-stratification, treatment, and supportive care for patients with polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF). Risk-stratified treatment algorithms are provided for each disorder.

This guideline provides recommendations on the management of adult and pediatric patients who are experiencing febrile neutropenia as a result of cancer treatment. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

This is a clinical practice guideline for patients with hairy cell leukemia. The guideline provides recommendations regarding diagnosis, initial treatment, response assessment and additional therapy, second-line therapy for relapsed/refractory or progressive disease, and supportive care. The impact of infections, such as hepatitis B (HBV) is also discussed.

This is a clinical practice guideline for women with cervical cancer. The guideline examines the initial diagnosis and workup, staging, primary and adjuvant treatment, surveillance, and therapy following relapse for these patients. Treatment for metastatic disease is also discussed, as are the topics of incidental cervical cancer and the occurrence of cervical cancer in pregnant women.

This is a clinical practice guideline for patients with cancer who are at risk of infertility due to anticancer treatment. The guideline examines fertility preservation options for this patient population. Topics discussed include options for men and women, special considerations for children, as well as the role of the health care provider.

This is a clinical practice guideline for patients aged 16 or older who have primary brain tumours or brain metastases. Specifically, the guideline examines the diagnoses and management of radiologically identified glioma, meningioma, and brain metastases. Follow-up care after treatment and supportive care are also discussed, and additional recommendations are provided on the referral of adults with primary brain tumours or brain metastases for neurological rehabilitation assessment.

This is a clinical practice guideline for adults and children experiencing cancer-related fatigue (CRF). The guideline discusses screening for CRF, as well as evaluation approaches using focused history, assessment of treatable contributing factors, and patient clinical status. General strategies for managing CRF are discussed, and the guideline examines pharmacological and non-pharmacological treatments for patients based on their placement within the care continuum (i.e. active treatment, post-treatment, and end-of-life).

This is a clinical practice guideline for patients with pancreatic adenocarcinoma. The guideline examines risk factors and genetic predisposition, pancreatic cancer screening, diagnosis and staging, systemic therapy approaches, radiation and chemoradiation approaches, surveillance of patients with resected disease, as well as palliative and supportive care. Management of metastatic disease, locally advanced disease, resectable and borderline resectable disease, and recurrent disease after resection is also considered.

This is a clinical practice guideline for patients with myelodysplastic syndromes (MDS). The guideline discusses diagnostic classification, evaluation, prognostic stratification, therapeutic options, and recommended treatment approaches for MDS. There is a particular focus on supportive care, and the guideline also provides recommendations for the management of thrombocytopenia and iron overload, the treatment of related anemia, the use of low-intensity therapy (i.e. hypomethylating agents or biologic response modifiers and immunosuppressive therapy), and high-intensity therapy.

This is a clinical practice guideline for patients with multiple myeloma. The guideline examines the primary therapy and surveillance/follow-up tests for both solitary plasmacytoma and smoldering (asymptomatic) myeloma, and the primary therapy and monitoring for active (symptomatic) myeloma. Stem cell transplants (SCT), including autologous SCT, tandem SCT, and allogeneic SCT, as well as follow-up after stem cell transplants, are also discussed. In addition, the guideline considers diagnostic tests, response criteria, maintenance therapy, treatment of progressive or relapsed myeloma, and supportive care treatment.

This is a clinical practice guideline for patients with head and neck cancers. The guideline examines workup and staging, treatment, and follow-up for various head and neck cancers including cancer of the lip, oral cavity, oropharynx, hypopharynx, nasopharynx, and larynx, as well as paranasal tumours, very advanced head and neck cancers, occult primary cancer, salivary gland tumours, and mucosal melanoma of the head and neck. Nutrition, supportive care, comorbidities, quality of life, and dental evaluation and management are also discussed.

This is a clinical practice guideline for adult and pediatric patients with cancer. The guideline examines the practicality of palliative care delivery models for these patients and their family caregivers in resource-constrained settings. Recommendations are provided for palliative care models at the district, regional, and national level, as well as in the primary health care setting. For each model, the timing for addressing palliate care needs as well as the workforce, knowledge, and skills required are discussed. Nurses' roles in pain management, as well as spiritual care, social work/counseling, and opioid availability are also considered.

This is a clinical practice guideline for adolescents and young adults with cancer. The guideline discusses risk factors, screening, diagnosis, management, follow-up, supportive care, and palliative care for patients between 15 and 39 years of age. Unique issues discussed include adherence to treatment, the impact of cancer and its treatment on fertility, management of cancer during pregnancy, relationship management, and socioeconomic issues.

This is a clinical practice guideline for adults and children with cancer-induced anemia (CIA). The guideline discusses the etiology of CIA, and examines the screening, evaluation, and treatment methods for reducing CIA in affected patients. Red blood cell transfusion, erythropoietic therapy, and iron monitoring and supplementation are discussed as treatment options.

This is a clinical practice guideline for patients with AIDS-related Kaposi sarcoma. The guideline examines diagnosis, staging, treatment, and follow-up, while also providing recommendations on HIV screening and HIV therapy during cancer treatment. Antiretroviral therapy (ART), topical therapies, intralesional chemotherapy, local incisions, radiation therapy, and systemic therapy are all discussed as treatment options.

This is a clinical practice guideline for the practical assessment and management of vulnerabilities in older patients undergoing chemotherapy. The guideline examines whether geriatric assessment (GA) should be used in older adults with cancer to predict adverse outcomes from chemotherapy, which GA tools should be used, and which general life expectancy data should be considered in order to estimate mortality and best inform treatment decision-making.

This is a guideline for facilitating collaborative and effective family involvement in the cancer setting. The guideline examines practical strategies to guide effective communication for the clinician-patient-family trio, and specifically addresses the positive and effective involvement of adult patients' family caregivers in consultations and patient care.

This is a clinical practice guideline for the diagnosis and management of early and locally advanced breast cancer. The guideline provides recommendations on referral, diagnosis, preoperative assessment, genetic testing, surgical procedures, breast reconstruction, psychological support, and adjuvant therapies such as endocrine therapy and bisphosphonate therapy.

This is a clinical practice guideline for adult patients with chronic lymphocytic leukemia. The guideline examines the diagnostic and staging criteria, treatment strategies, and follow-up and supportive care practices for these patients. First and second line treatment options are discussed for newly diagnosed, relapsed, and refractory disease.

This is a clinical practice guideline for adolescent, young adult (AYA), and adult patients with acute lymphoblastic leukemia (ALL). The guideline reviews the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers, and provides recommendations on risk assessment and stratification for risk-adapted therapy, as well as treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL. The guideline also provides recommendations for supportive care.

This is a clinical practice guideline for adult cancer survivors and those living with advanced disease. The guideline examines the screening, diagnosis and management of cancer-related pain in these patients. Specific topics addressed include the frequency of pain screening, support for patient self-management, as well as patient-specific, multimodal treatment plans.

This is a clinical practice guideline for patients with multiple myeloma. The guideline examines the primary therapy and surveillance/follow-up tests for both solitary plasmacytoma and smoldering (asymptomatic) myeloma, and the primary therapy and monitoring for active (symptomatic) myeloma. Stem cell transplants (SCT), including autologous SCT, tandem SCT, and allogeneic SCT, as well as follow-up after stem cell transplants, are also discussed. In addition, the guideline considers diagnostic tests, response criteria, maintenance therapy, treatment of progressive or relapsed myeloma, and supportive care treatment.

This is a clinical practice guideline for patients with acute myeloid leukemia (AML), including those with acute promyelocytic leukemia (APL). The guideline examines the initial evaluation of AML, risk stratification based on cytogenetics and molecular markers, management options, as well as supportive care. Management strategies are separated based on whether patients are above or below sixty years of age.

This is a clinical practice guideline for adult patients who are experiencing immune suppression or increased susceptibility to infection as a result of cancer or and/or its treatment. The guideline discusses antimicrobial prophylaxis and the potential impacts on reducing the incidence of and mortality from febrile neutropenia (FN). Fluoroquinolone, oral triazole, antivirals, and neutropenic diets are all examples of management options that are discussed.

This is a clinical practice guideline for adults with newly-diagnosed or recurrent oesophago-gastric cancer. The guideline discusses clinical assessment, radical and palliative treatment, follow-up, nutritional support, and service organization. The primary outcomes of interest are increases in quality of life and survival.

This is a clinical practice guideline for patients with chronic lymphocytic leukemia (CLL). The guideline provides recommendations on treatment and supportive care for these patients. Specific topics discussed include the initial approach to patient management, clinical and molecular assessment prior to treatment, front-line therapies, treatment of extremely frail patients, maintenance therapy, management of relapsed or refractory CLL, and management of side-effects during targeted therapy.

This is a clinical practice guideline for patients living with HIV (PLWH) who are diagnosed with cancer. The guideline focuses primarily on PLWH who develop non-small cell lung cancer (NSCLC), anal cancer, Hodgkin lymphoma, or cervical cancer. General advice is also provided regarding HIV management during cancer therapy, in addition to topics such as drug-drug interactions (DDI) between antiretroviral treatments and cancer therapies, initial workup, radiation therapy, surgical management, and supportive care.

This is a clinical practice guideline for adults with any type of cancer. The guideline focuses on the screening, assessment, and treatment of cancer-related pain. Specific topics discussed include universal pain screening, management of pain in both opioid-naïve and opioid-tolerant patients, management of opioid-induced adverse effects, procedure-related pain and anxiety, management strategies for specific cancer pain syndromes, adjuvant analgesics for neuropathic pain, psychosocial support, and education for both patients and caregivers.

This is a clinical practice guideline for survivors of childhood, adolescent, and young adult cancers. The guideline provides recommendations for the screening and management of therapy-related complications or adverse effects that persist or arise after the completion of treatment (i.e. late effects). Different therapeutic exposures and their potential late effects are explored and organized by cancer site and type of exposure (e.g. chemotherapy, radiation).

This is a clinical practice guideline for patients with myeloproliferative neoplasms. The guideline specifically examines the diagnosis, risk-stratification, treatment, and supportive care for patients with polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF). Risk-stratified treatment algorithms are provided for each disorder.

This is a clinical practice guideline for patients with myelodysplastic syndromes (MDS). The guideline discusses diagnostic classification, evaluation, prognostic stratification, therapeutic options, and recommended treatment approaches for MDS. There is a particular focus on supportive care, and the guideline also provides recommendations for the management of thrombocytopenia and iron overload, the treatment of related anemia, the use of low-intensity therapy (i.e. hypomethylating agents or biologic response modifiers and immunosuppressive therapy), and high-intensity therapy.

This is a clinical practice guideline for adult patients with active cancer. The guideline examines screening, assessment, and management strategies for cancer-related pain of any severity in these patients. Pharmacological management options discussed include acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs), adjuvant analgesics, opioid drugs, and management of cancer pain in patients with renal impairment. Non-pharmacological management options including radiotherapy, vertebroplasty and kyphoplasty, anesthetic interventions, surgical interventions, and complementary therapies are also discussed. The guideline also considers supportive care of these patients.

This is a clinical practice guideline for older patients with cancer. The guideline provides recommendations for comprehensive geriatric assessments, as well as treatment modalities such as surgery, radiation therapy (RT), chemotherapy, and targeted therapy. Disease-specific issues are also addressed for breast cancer, central nervous system cancers, gastrointestinal cancers, genitourinary cancers, gynecological cancers, head and neck cancers, lung cancers, melanoma, and hematologic malignancies.

This is a clinical practice guideline examining communication strategies for clinicians who are treating adult cancer patients. The guideline specifically addresses the management of challenging interactions between clinicians and the family caregivers of adult cancer patients. Types of challenges examined include those involving family dysfunction, anger, and conflicting treatment wishes.

This is a clinical practice guideline for patients living with HIV (PLWH) who are diagnosed with cancer. The guideline focuses primarily on PLWH who develop non-small cell lung cancer (NSCLC), anal cancer, Hodgkin lymphoma, or cervical cancer. General advice is also provided regarding HIV management during cancer therapy, in addition to topics such as drug-drug interactions (DDI) between antiretroviral treatments and cancer therapies, initial workup, radiation therapy, surgical management, and supportive care.

This is a clinical practice guideline for patients with pancreatic adenocarcinoma. The guideline examines risk factors and genetic predisposition, pancreatic cancer screening, diagnosis and staging, systemic therapy approaches, radiation and chemoradiation approaches, surveillance of patients with resected disease, as well as palliative and supportive care. Management of metastatic disease, locally advanced disease, resectable and borderline resectable disease, and recurrent disease after resection is also considered.

This is a clinical practice guideline for adults with suspected pancreatic cancer, or those with newly diagnosed or recurrent pancreatic ductal adenocarcinoma. The guideline provides recommendations for the monitoring of people with an inherited high risk of pancreatic cancer. Recommendations are also made for diagnosis, staging, psychological support, pain and nutrition management, as well as management for resectable, borderline resectable, and unresectable cancer.

This is a clinical practice guideline for adults with cancer who are at risk for, or have been diagnosed with, delirium. The guideline provides recommendations regarding delirium prevention, diagnosis, screening, treatment and experiential impact. Pharmacological and non-pharmacological interventions are discussed. Guidance is also provided on education and support for the healthcare team and family members.

This is a clinical practice guideline for the identification and treatment of psychosocial problems in patients with cancer. The guideline examines screening tools for distress and meeting psychosocial needs, the initial evaluation and treatment by oncology teams, psychological/psychiatric treatment by mental health professionals, social work and counseling services, and spiritual and chaplaincy care. The Distress Thermometer (DT) is discussed as a useful clinical tool for self-assessing patient distress. Both the DT and the guideline itself use the term "distress" due to its lack of associated stigmatization when compared to terms such as psychosocial, psychiatric, or emotional.

This is a clinical practice guideline for patients with any type of cancer who are experiencing or are at high risk for experiencing nausea and/or vomiting due to treatment. The guideline examines treatment options for nausea and/or vomiting induced by radiation therapy (RT), chemotherapy, targeted therapy, and immunotherapy. In addition to antiemetic treatment options, the guideline discusses the emetogenic potentials of different anticancer therapies.

This is a clinical practice guideline for patients with gastric cancer. The guideline examines the pathology, initial workup, staging, treatment, follow-up, and supportive care of these patients. Treatment options discussed include lymph node dissection, laparoscopic resection, endoscopy, radiation therapy, combined modality therapy, chemotherapy (preoperative, perioperative, and postoperative), and targeted therapies.

This is a clinical practice guideline for patients who are receiving systemic anticancer therapy. The guideline examines the management of infusion reactions (IRs), which can be either allergic reactions to foreign proteins, or non-immune-mediated reactions. Specific topics discussed include risk assessment, diagnosis, management, how to document an IR, drugs which may frequently cause IRs, and cases of rechallenge.

This is a clinical practice guideline discussing the treatment and prophylaxis of venous thromboembolism (VTE) in patients receiving treatment for solid (i.e. non-hematologic) tumours. The guideline examines the pharmacologic therapy and dosing options for both inpatients and ambulatory patients with established VTE or who are at risk for VTE (i.e. prophylaxis). The guideline also discusses common complications associated with antithrombotic therapy, as well as the follow-up of patients during its administration.

This is a clinical practice guideline for adult and pediatric patients who receive antineoplastic agents or radiation therapy for cancer. The guideline examines important developments in antiemetic management options for patients undergoing the above treatments. Comparisons are made between antiemetic management options on the basis of potential benefits, potential harms, and quality of evidence. Outcomes of interest include new evidence regarding antiemetic efficacy and new antiemetic management options.

This is a clinical practice guideline for the management of localized prostate cancer. The guideline provides a clinical framework stratified by cancer severity to guide the care plan and reviews management options including active surveillance, observation/watchful waiting, prostatectomy, radiotherapy, cryosurgery, high intensity focused ultrasound (HIFU), and focal therapy. Shared decision making is highlighted, and guidance is provided on outcome expectations and management.

This is a clinical practice guideline for adult patients who have undergone cancer treatment, and are at risk for developing secondary upper quadrant lymphedema (SUQL). The guideline provides recommendations for the diagnosis of SUQL, using methods such as clinical examination and patient-reported symptom assessments, bioimpedance analysis, circumferential measurement, water displacement, and imaging techniques such as magnetic resonance imaging (MRI), and computed tomography (CT). The primary outcomes of interest are decreases in both morbidity as well as activity and participation restrictions, and an increase in overall quality of life (QOL).

This is a clinical practice guideline for the management of adult patients after head and neck cancer (HNC) treatment. Recommendations address surveillance and screening for recurrence of second primary cancers, assessment and management of physical and psychosocial long-term and late effects of HNC and treatment, health promotion, as well as care coordination and implications for practice. The guideline emphasizes the need for a multidisciplinary, coordinated, and collaborative care team for the delivery of effective HNC survivorship care.

This is a clinical practice guideline for patients with myeloma. The guideline examines the screening and management of physical and psychosocial consequences in these patients following completion of treatment. Recommendations are provided for long-term physical consequences, including infection and immunity, renal and urogenital complications, bone, endocrine and metabolic disorders, neurological and eye complications, cardiovascular and respiratory complications, dental and oral hygiene, gastroenterological and nutritional problems, and second primary malignancies. Psychosocial and rehabilitation considerations such as frailty, patient concerns and information provision, psychological well-being, pain and fatigue, and physical fitness and functionality are also discussed.

Tailored to the unique needs and concerns of patients with all types of cancer, this clinical practice guideline provides standard-of-care recommendations, techniques, and strategies on smoking cessation. The guideline outlines different interventions, including pharmacotherapy options (e.g. nicotine replacement therapy, varenicline, bupropion, nortriptyline, clonidine), motivational strategies and behaviour techniques, and alternative treatment approaches such as electronic cigarettes and other electronic nicotine delivery systems.

This is a clinical practice guideline for patients with hairy cell leukemia. The guideline provides recommendations regarding diagnosis, initial treatment, response assessment and additional therapy, second-line therapy for relapsed/refractory or progressive disease, and supportive care. The impact of infections, such as hepatitis B (HBV) is also discussed.

This clinical practice guideline is an adaptation of Cancer Care Ontario’s 2016 guideline titled Interventions to Address Sexual Problems in People With Cancer. The guideline examines the effectiveness of pharmacological interventions, psychosocial counseling, or devices to manage sexual problems experienced after cancer treatment. Recommendations are based on patient gender, and condition. Specific topics discussed are sexual response, body image (women), intimacy/relationships, overall sexual functioning and satisfaction, vasomotor symptoms, genital symptoms (women) and genital changes (men).

This is a clinical practice guideline for adults who have completed treatment and have been cured of cancer. The guideline examines different models of follow-up care, organized both by clinical setting, and by which health professionals are responsible for the coordination of care. The appropriateness of different models of care for different types of cancer is discussed, with focuses on clinical outcomes (e.g. surveillance, recurrence) and quality of life outcomes (e.g. quality of life, patient satisfaction).

This is a clinical practice guideline for patients with epithelial ovarian-type cancers (e.g. ovary, fallopian tube or peritoneal origin) and borderline tumours. This guideline addresses epithelial cancers of varying histological subtypes. The guideline covers the full continuum of care including screening and prevention, diagnosis, treatment options such as surgery, systemic therapy and chemotherapy, follow-up, as well as management of recurrent disease. The guideline also highlights the support needs for women with ovarian cancer.

This is a clinical practice guideline for patients with hematologic malignancies and/or patients who underwent hematologic stem cell transplantation (HSCT). who are at risk for hepatitis B virus (HBV) infection reactivation. The guideline provides recommendations on HBV screening, monitoring, prophylaxis, treatment and vaccination in these patients. The primary outcome of interest is the prevention of hepatic failure and death caused by HBV reactivation.

This is a clinical practice guideline for oncology clinicians on how to use effective communication to optimize the patient-clinician relationship, patient and clinician well-being, and family well-being. The guideline examines the core communication skills and tasks that apply across the continuum of cancer care. Topics include the discussion of goals of care and prognosis, treatment selection, end-of-life care, facilitating family involvement in care, and clinician training in communication skills.

This is a clinical practice guideline for adults and children who are taking anti-resorptive or anti-angiogenic medications. The guideline, aimed at dental care practitioners, provides recommendations for reducing the risk of medication-related osteonecrosis of the jaw (MRONJ) in these patients. Risk factors for MRONJ are discussed, and recommendations are provided for assessing and classifying patients' risk.

This is a clinical practice guideline for patients with Waldenström macroglobulinemia (WM). The guideline examines the diagnosis and treatment of these patients. Common presentations, diagnostic criteria, prognostic markers, as well as diagnostic workup using protein studies and bone marrow biopsy are considered. Therapeutic regiments are discussed for front-line therapy of WM and treatment of relapsed WM, as well as important management aspects unique to WM.

This is a clinical practice guideline for patients with head and neck cancer. The guideline examines the optimal perioperative care for patients undergoing head and neck cancer surgery with free flap reconstruction. Specific topics discussed include preadmission education, perioperative nutritional care, preoperative nutritional status, nutritional formulae, prophylaxis against thromboembolism, and antibiotic prophylaxis.

This is a clinical practice guideline for adults with cancer-related fatigue. The guideline examines the appropriate screening, assessment, and management of these patients. Interventions discussed include pharmacological management, physical activity, functional and occupational therapy interventions, psychosocial and educational interventions, complementary therapies, nutrition, and management of anemia. Recommendations are provided based on the severity of fatigue.

This is a clinical practice guideline for adults and children with cancer-induced anemia (CIA). The guideline discusses the etiology of CIA, and examines the screening, evaluation, and treatment methods for reducing CIA in affected patients. Red blood cell transfusion, erythropoietic therapy, and iron monitoring and supplementation are discussed as treatment options.

This is a clinical practice guideline for adult patients with lung cancer who have been treated with surgery or systemic anti-cancer treatment such as chemotherapy or (external-beam) radiotherapy. The guideline provides recommendations for the symptomatic management of persistent, bothersome cough among theses patients. Multiple options for reducing cough are discussed, based on the etiology of the cough and the patient's response to various treatments.

This is a clinical practice guideline for women with uterine cancer. The guideline provides recommendations for the screening and prevention of uterine cancer in the general population and in high risk groups, as well as for the pathological work-up, management, and follow-up of patients with uterine cancer. Specific conditions discussed include endometrioid endometrial cancer, as well as non-endometrioid cancers such as uterine serous carcinoma, uterine clear cell carcinoma, and uterine carcinosarcoma.

This is a clinical practice guideline for patients with myeloproliferative neoplasms. The guideline specifically examines the diagnosis, risk-stratification, treatment, and supportive care for patients with polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF). Risk-stratified treatment algorithms are provided for each disorder.

This is a clinical practice guideline for the management of non-metastatic muscle-invasive urothelial bladder cancer in adults. The guideline examines the initial evaluation, treatment, follow-up, and survivorship of affected patients, and discusses approaches to counseling and the role of patient preferences throughout. Specific treatment options considered include neoadjuvant and adjuvant chemotherapy, radical cystectomy, pelvic lymphadenectomy, and bladder preserving approaches such as maximal transurethral resection of bladder tumours, partial cystectomy, primary radiation therapy, and multi-modal bladder preserving therapy.

This is a clinical practice guideline for patients with hepatitis C virus (HCV) infection who are candidates for liver transplantation (LT). Specifically, the guideline provides recommendations on the treatment of patients with compensated cirrhosis and hepatocellular carcinoma (HCC), the treatment of patients with decompensated cirrhosis with or without HCC, the management of HCV in the context of an anti-HCV-positive donor, the treatment of post-transplant severe cholestatic hepatitis, the treatment of recurrent HCV infection, the treatment of recurrent HCV cirrhosis, and the treatment of HCV pre- and post-LT in human immunodeficiency virus (HIV)-HCV co-infected patients. Outcomes of interest differ between specific patient populations, and include wait-list mortality, post-LT survival, HCV recurrence post-LT, and the development of extrahepatic complications.

A clinical practice guideline for the treatment of small cell and non-small cell lung cancer. The guideline examines treatment options for multiple stages of these two cancer modalities, including surgical and non-surgical procedures. Palliative, supportive, and psychological care for lung cancer patients are also discussed. This guideline is wiki-based and is constantly updated as new evidence arises - this review pertains to the guideline as of April 23, 2018.

This is a clinical practice guideline for patients who have received initial treatment for chordomas, who are at risk for loco-regional recurrence. The guideline provides recommendations for pre-treatment assessment, resection of recurrent or progressive disease, radiotherapy of recurrence, other local therapies, follow-up, as well as for palliative, supportive and end-of-life care. Outcomes of interest include quality of life, recurrence-free survival, and overall survival.

This is a clinical practice guideline for adolescents and young adults with cancer. The guideline discusses risk factors, screening, diagnosis, management, follow-up, supportive care, and palliative care for patients between 15 and 39 years of age. Unique issues discussed include adherence to treatment, the impact of cancer and its treatment on fertility, management of cancer during pregnancy, relationship management, and socioeconomic issues.

This clinical practice guideline provides recommendations for breast reconstruction in women following mastectomy for the prevention or treatment of breast cancer. The guideline discusses patient education, eligibility for reconstruction, timing of reconstruction, factors that enhance recovery from reconstruction, post-reconstruction surveillance, and measuring outcomes of construction. The benefits and risks of implant-based, autologous flap, and combination reconstruction procedures are examined. The guideline also discusses the extent to appropriately perform mastectomy.

This is a clinical practice guideline for children with cancer. The guideline examines the effective delivery of education to these patients and their families. Educational methods, time after initial diagnosis, location, and educational content are considered. The influence of demographic and/or clinical attributes of these patients and their families on the successful transfer of initial educational information is discussed, as are interventions that have been developed to improve the comprehensiveness of information related to diagnosis, treatment, and care of these patients.

This clinical practice guideline provides recommendations for the diagnosis and treatment of acute myeloid leukemia (AML). Induction therapy and post-remission (consolidation) therapy are reviewed with recommendations stratified by risk and age. Specific recommendations are provided for the management of acute promyelocytic leukemia (APL). The guideline also discusses therapy for relapse, evaluation and treatment of CNS leukemia, and supportive care.

This clinical practice guideline reviews diagnostic assessment and management of prostate cancer. The guideline discusses risk stratification, molecular testing, and imaging for clinical assessment and staging workup. Management options reviewed include observation, active surveillance, radical prostatectomy, radiation therapy, androgen deprivation therapy, chemotherapy, and immunotherapy, with treatment recommendations stratified by risk. Outcomes of interest include survival and adverse effects of treatment.

A clinical practice guideline for adult patients with chronic lymphocytic leukemia. The guideline examines diagnosis, staging, and treatment of newly diagnosed, relapsed, and refractory leukemia. Outcomes of interest include progression-free survival, reduced adverse events, and treatment response.

This clinical practice guideline discusses specific issues related to the management of cancer in adults aged 65 years or older. Topics include screening and comprehensive geriatric assessment (CGA), assessing risks and benefits of treatment, preventing or decreasing complications from therapy, and managing disease-specific issues. Recommendations are also provided for management of patients deemed to be at high risk for toxicity from standard treatment.

This is a clinical practice guideline for women with vulvar cancer (VC) or vulvar intraepithelial neoplasia (VIN). The guideline provides recommendations for symptom management, with an emphasis on self-management interventions. Specific topics discussed include the handling of surgical wounds, as well as the management of acute postsurgical pain, postsurgical urinary symptoms, and lymphedema.

This is a clinical practice guideline for patients undergoing major head and neck cancer surgery with free flap reconstruction. The guideline provides recommendations for the optimal perioperative care of these patients, focusing on topics such as preadmission education, preoperative nutritional status, perioperative nutritional care, prophylaxis against thromboembolism, antibiotic prophylaxis, postoperative nausea and vomiting prophylaxis, standard anesthetic protocol, pain management, postoperative wound care, postoperative pulmonary physical therapy, and more.

A clinical practice guideline for the prevention of chemotherapy and radiotherapy-induced nausea and vomiting in advanced cancer patients. The guideline examines the emetogenic potential of antineoplastic agents and recommended pharmacological treatments. Outcomes of interest include antiemetic prophylaxis, efficacy, and optimal dosing.

This is a clinical practice guideline for soft tissue sarcoma. The guideline examines diagnosis, treatment and follow up. Various stages are addressed, as well as a various treatment options and disease progression. Guidance is presented for specific issues (e.g., gastrointestinal stromal tumors).

This is a clinical practice guideline for patients (children/adolescents and adults) who are experiencing cancer-related fatigue. The guideline discusses evaluation and intervention for patients on active treatment, post-treatment, and at end of life. Education and counselling, nonpharmacologic interventions, and pharmacologic interventions are all discussed along with general strategies for management of fatigue.

This clinical practice guideline provides recommendations on assessment and management of cancer pain in adult patients, including pain in adult cancer survivors. Pathophysiologic classification of cancer pain syndromes is reviewed, and recommendations are provided for pain assessment, management/intervention, and reassessment. Both pharmacologic and non-pharmacologic interventions are discussed.

This is a clinical practice guideline for gastric cancer. The guideline provides an evidence- and consensus-based treatment approach for the management of patients with gastric cancer. Topic areas discussed within the guideline include: staging, principles of pathology, surgery, endoscopic therapies, radiation therapy, combined modality therapy, chemotherapy, and follow-up.

This is a clinical practice guideline for the investigation and diagnosis of suspected lung cancer and referral for treatment, particularly for patients residing in Nova Scotia. The guideline reviews the investigation process from initial presentation to treatment referral. Topics include principles of communication between patient-provider and among providers throughout the diagnostic process, standards for initial investigation, appropriate use of imaging (CT, MRI, PET, bone scan) and biopsy and laboratory testing, as well as recommendations regarding treatment referral upon diagnosis. Referrals to diagnostic specialists (thoracic surgery or respirology) and to psychosocial and supportive care are also reviewed.

This is a clinical practice guideline for individuals at risk of or having genetic mutations that increase their risk of breast or ovarian cancer. The guideline reviews hereditary breast or breast/ovarian cancer syndrome, Li-Fraumeni syndrome, Cowden syndrome/PTEN Hamartoma tumor syndrome, and other genetic mutations associated with breast/ovarian cancer. Recommendations are provided for initial risk assessment, formal risk assessment and genetic counselling, and management options for individuals with a clinical diagnosis following genetic testing.

This is a clinical practice guideline for the management of chronic pain in survivors of adult cancers. Whereas other guidelines have largely focused on relieving acute pain or pain associated with advanced disease, this guideline focuses on the care required when pain persists months or years after the completed cancer treatment. Areas addressed in the guideline include: screening and comprehensive assessment; treatment and care options; nonpharmacologic interventions; pharmacologic interventions; as well as risk assessment, mitigation, and universal precautions with opioid use.

This is a clinical practice guideline for patients with colon cancer or adenocarcinomas of the small bowel and appendix. The guideline reviews staging, pathology, clinical presentation and treatment of nonmetastatic disease, management of metastatic disease, post-treatment surveillance, and survivorship. The role of vitamin D in colorectal cancer is also discussed.

This clinical practice guideline reviews workup, staging, and treatment for both noninvasive and invasive breast cancer. Special considerations include phyllodes tumor, Paget's disease, breast cancer during pregnancy, and inflammatory breast cancer. Treatment recommendations for invasive cancer are stratified by tumor receptor status and stage. Fertility and birth control is also discussed.

The guideline provides recommendations for management and treatment of patients 18 years of age and older who have malignant superior vena cava obstruction (SVCO) or airway obstruction, compression, or invasion, or those experiencing hemoptysis. The course of management is dependent on symptoms, primary histology, urgency of histology, previous treatment, and access to resources. External beam radiotherapy (EBRT), endobronchial brachytherapy, chemotherapy, radiotherapy, bronchoscopic debulking, surgical resection, photodynamic therapy, and Neodymium-doped yttrium aluminum garnet (Nd:YAG) are discussed as treatment options. For superior vena cava obstruction, external beam radiation EBRT, RT dose fractionation, SVC stent insertion, steroids, and palliative intent chemotherapy are discussed.

This is a clinical practice guideline on the identification and treatment of psychosocial problems in patients with cancer. The guideline discuss screening tools for distress, initial evaluation and treatment by the oncology team, psychological/psychiatric treatment by mental health professionals, social work and counselling services, and spiritual and chaplaincy care. Psychological/psychiatric treatment guidelines are reviewed. Special topics of interest include oncologist burnout.

The American Cancer Society Head and Neck Cancer Survivorship Care Guideline was developed to assist primary care clinicians and other health practitioners with the care of head and neck cancer survivors, including monitoring for recurrence, screening for second primary cancers, assessment and management of long-term and late effects, health promotion, and care coordination. The guideline provides recommendations for management strategies for assisting patients with physical and psychosocial effects of head and neck cancer and its treatment.

This is a clinical practice guideline for antiemesis. The guideline examines emesis, types of nausea/vomiting (e.g., chemotherapy induced), antiemetic therapies, and treatment issues associated with antiemetic therapies.

This is a clinical practice guideline for myelodysplastic syndromes (MDS). The guideline provides an update to recommendations on standard approaches to the diagnosis and treatment of MDS in both children and adults. The guideline discusses evaluation and prognostic stratification, Topics of interest include prognostic stratification, evaluation of related anemia and treatment of symptomatic anemia, and supportive care. Molecular abnormalities in MDS and comorbidity indices are also discussed.

These clinical practice guidelines for survivorship provide screening, evaluation, and treatment recommendations for common consequences of cancer and cancer treatment to aid health care professionals who work with survivors of adult-onset cancer in the post-treatment period, including those in specialty cancer survivor clinics and primary care practices. The guidelines focus on the vast and persistent impact both the diagnosis and treatment of cancer can have on the adult survivor’s health, physical and mental states, health behaviors, professional and personal identity, sexuality, and financial standing.

This is a clinical practice guideline for patients with cervical cancer including squamous cell carcinoma, adenosquamous carcinoma, and adenocarcinoma of the cervix. The guideline discusses diagnosis and workup, principles of staging and surgery, primary treatment, adjuvant treatment, surveillance, and therapy for relapse. Special topics of consideration include incidental cervical cancer, radiation therapy, and cervical cancer and pregnancy.

This is a clinical practice guideline for adults and children who are receiving hematopoietic stem cell transplantation (HSCT) or are undergoing treatment for hematological malignancies. The guideline provides recommendations for the diagnosis, prevention, and management of common respiratory viral infections in these patients. Diseases discussed include influenza, respiratory syncytial virus (RSV), human metapneumovirus (HMPV), human parainfluenza virus (HPIV), and human rhinovirus (HRV).

This is a clinical practice guideline for children aged 1 month to 18 years who are receiving chemotherapy. The guideline examines the management of chemotherapy-induced nausea and vomiting (CINV), including the treatment of breakthrough CINV and the prevention of refractory CINV. The primary outcome of interest is a decrease in the incidence of CINV.

This is a clinical practice guideline for adult men and women that have sexual function side effects as a result of cancer diagnoses and/or treatment. The guideline examines strategies/interventions to manage sexual function side effects with the aim of decreasing distress, and improving quality of life for cancer survivors and their partners. Both pharmacologic and non-pharmacologic interventions are discussed.

This is a clinical practice guideline for Hodgkin lymphoma. The guideline discusses the clinical management of patients with classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), focusing exclusively on patients from post adolescence through the seventh decade of life who do not have serious intercurrent disease. Areas considered and discussed within the guideline include: staging and prognosis, the role of PET scans, treatment, principles of radiation therapy, and follow-up after completion of treatment.

This is a clinical practice guideline for patients aged 15 or older with acute lymphoblastic leukemia (ALL). The guideline reviews diagnosis, workup and risk stratification, treatment and consolidation therapy stratified by age and Philadelphia chromosome presence/absence, surveillance, treatment for relapse/refractory disease, and supportive care. The guideline discusses typical immunophenotyping panels for all major subtypes, and minimal residual disease assessment. Evaluation and treatment of extra medullary involvement is also reviewed.

This is a clinical practice guideline for women who are at increased risk of developing breast cancer. The guideline provides an overview on risk assessment, risk-reduction interventions including lifestyle interventions, risk-reduction surgery, and risk-reduction agents (tamoxifen, raloxifene, aromatase inhibitors). Recommendations are also provided for managing side effects of risk-reduction agents and monitoring for complications. Risk-reduction counselling is also discussed.

This guideline is for adult patients over 16 years of age with suspected, newly diagnosed, or relapsed myeloma. The guideline provides recommendations on laboratory and imaging investigations, management of newly diagnosed myeloma, managing acute renal disease caused by myeloma, preventing and managing complications, disease monitoring, and managing relapsed myeloma. Recommendations are also provided on service organization. Outcomes of interest include time to biochemical and/or clinical progression, overall survival, adverse events, quality of life and resource use.

This is a clinical practice guideline for male patients diagnosed with or suspected of having prostate cancer. The guideline reviews classification and staging, diagnostic evaluation, disease management, and follow-up care. Side effects of local treatment and health-related quality of life in prostate cancer survivors are also discussed. Outcomes of interest include overall survival, cancer-specific survival, development of metastatic disease, sensitivity and specificity of diagnostic procedures, and side effects of treatment.

A clinical practice guideline for adult and pediatric patients with cancer, including hematological cancers and solid tumours. The guideline examines pneumococcal immunization in order to prevent secondary infections. Outcomes of interest include reduced pneumonial mortality and improved immunization scheduling.

A clinical practice guideline for the diagnosis and treatment of acute lymphoblastic leukemia in adult and pediatric patients. The guideline examines diagnostic methods, treatment by age group, and special considerations including allogeneic stem cell transplantation and the role of cranial radiation. Outcomes of interest include probability of survival and incidence of hematological relapse.

This clinical practice guideline is for adolescents and young adults (AYAs), defined as individuals aged 15 to 39 years, who have been diagnosed with cancer. The guideline discusses issues specific to AYAs and recommends interventions unique to these patients. Topics include an overview of risk factors, screening, diagnosis, and special considerations for management of AYA patients such as adherence to treatment and fertility preservation, contraception for women during and after cancer treatment, and management of cancer during pregnancy. Psychosocial and behavioural issues, survivorship issues, and palliative and end-of-life care are also discussed.

This is a clinical practice guideline for smoking cessation in patients with cancer. The guideline emphasizes the importance of smoking cessation in all patients with cancer and seeks to establish evidence-based, standard of care recommendations tailored to the unique needs and concerns of patients with cancer. Treatment plans are provided that include recommendations that evaluate the merits of pharmacotherapy, behaviour therapy, and follow-up. The guideline developers acknowledge that smoking and nicotine addiction is a chronic relapsing disorder and as a result, the guideline also provides recommendations around retreatment and the management of relapse.

This clinical practice guideline reviews diagnosis and management of adenocarcinomas of the exocrine pancreas. Risk factors and genetic predisposition are discussed, and the guideline provides recommendations on screening, diagnosis and staging, and treatment options including systemic therapy, chemoradiation, and surgical management. Palliative and supportive care are also reviewed. Topics of interest include an overview of biomarkers, and suggestions for management of premalignant tumours of the pancreas.

This clinical practice guideline provides recommendations for evaluation, workup, management, and follow-up of 2 pathologic diagnoses in patients with epithelial occult primary cancer: adenocarcinoma or carcinoma not otherwise specified (NOS), and squamous cell carcinoma (SCC). Diagnostic tests are recommended based on disease location and patient gender. Treatment options for disseminated or localized disease for adenocarcinoma and site-specific SCC are also discussed.